Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Brain Neoplasms 11 Glioblastoma 3 Small Cell Lung Carcinoma 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Recurrence 1 Neurotoxicity Syndromes 1 Neoplasms, Germ Cell and Embryonal 1 Melanoma 1 Gliosarcoma 1 Gastrointestinal Neoplasms 1 Epilepsy 1 Ependymoma 1 Craniopharyngioma 1 Cognitive Dysfunction 1 Central Nervous System Neoplasms 1 Central Nervous System Carcinoma 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Temozolomide 23 Bevacizumab 18 Cyclophosphamide 9 Carboplatin 7 Lomustine 6 Irinotecan 6 3-Iodobenzylguanidine 6 Topotecan 5 Radiotherapy 5 Filgrastim 5 Radiosurgery 4 Nivolumab 4 Everolimus 4 Etoposide 4 Drug Therapy 4 Busulfan 4 sonidegib 3 pembrolizumab 3 olaparib 3 fludarabine phosphate 3 fludarabine 3 cemiplimab 3 antineoplaston AS 2-1 3 antineoplaston A10 3 Vincristine 3 Thiotepa 3 Sirolimus 3 Melphalan 3 IL13-PE38 3 Antilymphocyte Serum 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Memantine × CNS × Clear all

NCT01260467 2015-12-10

Memantine for Recurrent Glioblastoma

University of Rochester

Phase 2 Terminated

4 enrolled 3 charts

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡